First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

Vitolo U;Chiappella A;Ferreri AJ;Martelli M;Baldi I;Balzarotti M;Bottelli C;Conconi A;Gomez H;Lopez-Guillermo A;Martinelli G;Merli F;Novero D;Orsucci L;Pavone V;Ricardi U;Storti S;Gospodarowicz MK;Cavalli F;Sarris AH;Zucca E;;
journal of clinical oncology : official journal of the american society of clinical oncology 2011 Vol. 29 pp. -
457
u2011journalfirst-line

Abstract

This international prospective trial shows that combined treatment with R-CHOP21, IT-MTX, and testicular RT was associated with a good outcome in patients with PTL. RT avoided contralateral testis relapses, but CNS prophylaxis deserves further investigation.

Keywords

National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult male aged middle aged Recurrence Prospective Studies Clinical Trial Antibodies Monoclonal Multicenter Study Survival Analysis annalisa chiappella umberto vitolo murine-derived / administration & dosage murine-derived / adverse effects antineoplastic combined chemotherapy protocols / adverse effects cyclophosphamide / adverse effects doxorubicin / adverse effects lymphoma large b-cell prednisone / adverse effects vincristine / adverse effects methotrexate / administration & dosage pmid:21646602 doi:10.1200/jco.2010.31.4187 phase ii emanuele zucca antineoplastic combined chemotherapy protocols / therapeutic use* central nervous system neoplasms / prevention & control* central nervous system neoplasms / secondary cyclophosphamide / therapeutic use doxorubicin / therapeutic use drug-related side effects and adverse reactions diffuse / drug therapy* diffuse / pathology diffuse / radiotherapy methotrexate / adverse effects prednisone / therapeutic use rituximab testicular neoplasms / drug therapy* testicular neoplasms / pathology testicular neoplasms / radiotherapy vincristine / therapeutic use

Access

URL:
https://www.pubmed.gov/21646602/

Citation

ID: 113389
Ref Key: u2011journalfirst-line
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
113389
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store